Alexei Pushechnikov
Vice President MedChem Mair Therapeutics
Dr. Alexei Pushechnikov is an accomplished scientific and technology leader with over two decades of experience in drug discovery, medicinal chemistry, and process research. Throughout his career, Dr. Pushechnikov has held senior roles across the biotech and pharmaceutical ecosystem in the United States and Europe. Dr. Pushechnikov gained extensive experience in process chemistry and pilot-scale synthesis at Obiter Research and contributed to cancer therapy research at the International Institute of Nano and Molecular Medicine (University of Missouri), focusing on boron neutron capture therapy (BNCT).
He also served on the Board of Directors of Enamine Ltd., a global provider of chemical building blocks and screening libraries, where he also led customer relations and the establishment of contract biology services. Alexei also serves as a CTO of Expert System accelerator. Dr. Pushechnikov holds a PhD in Element-Organic Chemistry from the Research Institute of Organic Chemistry, National Academy of Sciences of Ukraine. He has authored multiple scientific publications in medicinal chemistry, structural biology, and pharmaceutical process development
Seminars
- Examining how biology, delivery constraints & safety risk shaped final modality choices
- Weighing durability, tissue access, reversibility & tolerability across competing strategies
- Identifying modality decision principles that remain consistent across CNS & peripheral programs
- Clarifying target rationale for lysosomal ion channels implicated in neurodegenerative disease to support early investment decisions
- Integrating electrophysiology, functional cell assays & chemistry iteration to progress intracellular channel hits toward development candidates
- Managing assay design & mechanistic uncertainty when optimizing compounds against non‑plasma membrane ion channels
- Achieving high brain penetrance while maintaining potency
- Clarifying target rationale for lysosomal ion channels implicated in neurodegenerative disease to support early investment decisions
- Integrating electrophysiology, functional cell assays & chemistry iteration to progress intracellular channel hits toward development candidates
- Managing assay design & mechanistic uncertainty when optimizing compounds against non‑plasma membrane ion channels
- Achieving high brain penetrance while maintaining potency
